IRTC241115C90000
- 1.74
- -1.01-36.73%
iRhythm Technologies Newsroom
IRhythm Technologies Analyst Ratings
Oppenheimer Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $145
Truist Financial Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Raises Target Price to $95
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Irhythm Technologies (IRTC)
Morgan Stanley Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $120
Irhythm Technologies Gains Buy Rating Following Regulatory Milestones
Baird Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Cuts Target Price to $100
Truist Financial Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Announces Target Price $80
Truist Cuts Price Target on IRhythm Technologies to $80 From $117, Keeps Buy Rating
Goldman Sachs Initiates IRhythm Technologies(IRTC.US) With Hold Rating, Announces Target Price $78
IRhythm Technologies Is Maintained at Buy by Canaccord Genuity
IRhythm Technologies Analyst Ratings
CCORF Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Raises Target Price to $137
Morgan Stanley Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $120
Oppenheimer Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $145
Oppenheimer Sticks to Their Buy Rating for Irhythm Technologies (IRTC)
IRhythm Technologies Analyst Ratings
Citi Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Cuts Target Price to $110
Wells Fargo Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $110
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and Irhythm Technologies (IRTC)